1999 world health organization-international society of hypertension guidelines for the management of hypertension

Journal of Hypertension

Volumn 17, Issue 2, 1999, Pages 151-183

  Chalmers, John ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Control; Evaluation; Hypertension; International Society of Hypertension; Lifestyle measures; Management guidelines; Treatment; World Health Organization

Indexed keywords

ALCOHOL; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOGEN; HYPOCHOLESTEROLEMIC AGENT; LIPID; LIPOPROTEIN;

AGE; ALCOHOL CONSUMPTION; ANTICOAGULANT THERAPY; ANTIHYPERTENSIVE THERAPY; ARTERY COMPLIANCE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM EXAMINATION; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL EVALUATION; COMMUNITY CARE; COMORBIDITY; CONGESTIVE HEART FAILURE; DEVELOPING COUNTRY; DIABETES MELLITUS; DIETARY INTAKE; DISEASE CLASSIFICATION; DRUG EFFICACY; ETHNIC GROUP; ETHNICITY; GENDER; GENE TARGETING; GEOGRAPHY; HEALTH CARE PLANNING; HEART DISEASE; HEART FAILURE; HIGH RISK PATIENT; HOME MONITORING; HORMONE SUBSTITUTION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; INTERMEDIATE RISK PATIENT; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LABORATORY TEST; LIFESTYLE MODIFICATION; LOW RISK PATIENT; MEDICAL HISTORY; MEDICAL SOCIETY; MEDICATION COMPLIANCE; MENTAL STRESS; MICROALBUMINURIA; MORBIDITY; OBESITY; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT PREFERENCE; PHYSICAL ACTIVITY; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; SMOKING; SMOKING CESSATION; SOCIOECONOMICS; SODIUM RESTRICTION; VERY ELDERLY; WEIGHT REDUCTION; WORLD HEALTH ORGANIZATION; ARTICLE; INTERNATIONAL COOPERATION; QUALITY OF LIFE; RISK FACTOR; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HUMANS; HYPERTENSION; INTERNATIONAL COOPERATION; QUALITY OF LIFE; RISK FACTORS; SOCIETIES, MEDICAL; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

EID: 0033069767     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.3109/10641969909061028     Document Type: Review

References (200)

1. Uemura K, Pisa Z. Trends in cardiovascular disease mortality in industrialised countries since 1 950. World Health Stat Q 1988; 41:155-168.
2. Burt VL, Cutler JA, Higgins M, Horan MJ, Labarthe D, Whelton P, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the Health Examination Surveys, 1960 to 1991. Hypertension 1995; 26:60-69.
3. Marques-Vidal P, Tuomilehto J. Hypertension awareness, treatment and control in the community: is the 'rule of halves' still valid? J Hum Hyperten 1997;11:213-220.
4. Colhoun HM, Dong W, Poulter NR. Blood pressure screening, manage-ment and control in England: results from the health survey for England 1994. J Hypertens 1998; 16:747-752.
5. Murray CJL, Lopez AD (editors). The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Geneva: World Health Organization; 1996.
6. WHO Expert Committee. Hypertension control, WHO Tech Rep Ser no. 862. Geneva: World Health Organization; 1996.
7. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood pressure, cholesterol and stroke in Eastern Asia. Lancet 1998;352:1801-1807.
8. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335:765-774.
9. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13, 000 strokes in 45, 000 people in 45 prospective cohorts. Lancet 1995; 346:1647-1653.
10. Kannel WB, Castelli WP, McNamara PM, McKee PA, Feinleib M. Role of blood pressure in the development of congestive heart failure. The Framingham Study. N Engl J Med 1972; 287:781-787.
11. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334:13-18.
12. Rodgers A, Neal B, MacMahon S. The effects of blood pressure lowering in individuals with cerebrovascular disease: an overview of randomised controlled trials. Neurol Rev Int 1997; 2:12-15.
13. Flack J, Neaton J, Grimm R, Shih J, Cutler J, Ensrud K, et al. for the Multiple Risk Factor Intervention Trial Research Group. Blood pressure and mortality among men with prior myocardial infarction. Circulation 1995;92:2437-2445.
14. Neal B, Clark T, MacMahon S, Rodgers A, Baigent C, Collins R, on behalf of the Antithrombotic Trialists' (ATT) Collaboration. Blood pressure and the risk of recurrent vascular disease [abstract]. Am J Hypertens 1998; 11:25A.
15. Irie K, Yamaguchi T, Minematsu K, Omae T. The J-curve phenomenon in stroke recurrence. Stroke 1993; 24:1844-1849.
16. Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet 1987; 1:581-583.
17. Benetos A, Safar M, Rudnichi A, Smulyan H, Richard JL, Ducimetiere P, et al. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension 1997; 30:1410-1415.
18. Madhavan S, Ooi WL, Cohen H, Alderman MH. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension 1994; 23:395-401.
19. Safar ME, London GM, Asmar R, Frohlich ED. Recent advances on large arteries in hypertension. Hypertension 1998; 32:156-161.
20. Blacher J, Pannier B, Guerin AP, Marchais SJ, Safar ME, London GM. Carotid arterial stiffness as a predictor of cardiovascular and all-cause mortality in end-stage renal disease. Hypertension 1998; 32:570-574.
21. Safar ME, Girerd X, Laurent S. Structural changes of large conduit arteries. J Hypertens 1996; 14:545-555.
22. Giannattasio C, Failla M, Mangoni AA, Scandola L, Fraschini N, Mancia G. Evaluation of arterial compliance in humans. Clin Exp Hypertens 1996; 18:347-362.
23. World Health Organization. World Health Statistics Annual. Geneva: World Health Organization; 1995.
24. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.
25. UK-TIA Study Group. The United Kingdom transient ischemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54:1044-1054.
26. The LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339:1349-1357.
27. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327:685-691.
28. Wong ND, Levy D, Kannel WB. Prognostic significance of the electrocardiogram after Q wave myocardial infarction: the Framingham Study. Circulation 1990; 81:780-789.
29. MacMahon S, Collins G, Rautaharju P, Cutler J, Neaton J, Prineas R, et al. for the Multiple Risk Factor Intervention Trial Research Group. Electro-cardiographic left ventricular hypertrophy and effects of antihypertensive drug therapy in hypertensive participants in the Multiple Risk Factor Intervention Trial. Am J Cardiol 1989; 63:202-210.
30. Levy D, Garrison R, Savage D, Kannel W, Castelli W. Prognostic implications of echocardiographies determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322:1561-1566.
31. Salonen JT, Salonen R. Ultrasonographically assessed carotid morphology and the risk of coronary heart disease. Arterioscler Thromb 1991; 11:1245-1249.
32. Zanchetti A, Agabiti-Rosei E, Dal Palu C, Leonetti G, Magnani B, Pessina A, for the VHAS Investigators. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomised treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 1998; 16:1667-1676.
33. Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Longford HG, et al. on behalf of the Hypertension Detection and Follow-up Program Group. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Hypertension 1989; 13 (Suppl I):I90-I93.
34. Samuelsson O, Wilhelmsen L, Elmfeldt D, Pennert K, Wedel H, Wikstrand J, et al. Predictors of cardiovascular morbidity in treated hypertension: results from the Primary Preventive Trial in Goteborg, Sweden. J Hypertens 1985;3:167-176.
35. US Renal Data System. USRDS 1997 Annual Report. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 1997.
36. Gall M-A, Borch-Johnsen B, Hougaard P, Nielsen FS, Parving H-H. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 1995; 44:1303-1309.
37. Stamler J, Vaccaro O, Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group. Diabetes, other risk factors, and 1 2-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16:434-444.
38. Abbott RD, Donahue RP, MacMahon SW, Reed DM, Yano K. Diabetes and the risk of stroke: the Honolulu Heart Project. JAMA 1987; 257:949-952.
39. Despres J-P, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, et al. Hyperinsulinemia is an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334:952-957.
40. Gerstein HC, Yusuf S. Dysglycaemia and risk of cardiovascular disease. Lancet 1996; 347:949-950.
41. Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ 1994; 309:901-911.
42. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994; 308:367-373.
43. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989; 79:8-15.
44. Rimm EB, Stampfer MJ, Ciovannucci E, Ascherio A, Spiegelman D, Colditz GA, et al. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. Am J Epidemiol 1995; 141:1117-1127.
45. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991; 325:373-381.
46. Stern MP, Haffner SM. Body fat distribution and hyperinsulinemia as risk factors for diabetes and cardiovascular disease. Arteriosclerosis 1986; 6:123-130.
47. Woodward M, Lowe GDO, Rumley A, Tunstall-Pedoe H. Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women: the Scottish Heart Health Study. Eur Heart J 1998; 19:55-62.
48. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993; 118:956-963.
49. Rimm ER, Klatsky A, Grobbee D, Stampfer MJ. Review of moderate alcohol consuption and reduced risk of coronary heart disease: is the effect due to beer, wine or spirits? BMJ 1996; 312:731-736.
50. Thun MJ, Peto R, Lopez AD, Monaco JH, Henley SJ, Heath CW, et al. Alcohol consumption and mortality among middle-aged and elderly US adults. N Engl J Med 1997; 337:1705-1714.
51. Wannamethee SG, Shaper AG. Patterns of alcohol intake and risk of stroke in middle-aged British men. Stroke 1996; 27:1033-1039.
52. Leon AS, Myers MJ, Connett J, for the MRFIT Research Group. Leisure time physical activity and the 16-year risks of mortality from coronary heart disease and all-causes in the Multiple Risk Factor Intervention Trial (MRFIT). Int J Sports Med 1997; 18 (Suppl 3):S208-S215.
53. Arakawa K. Effect of exercise on hypertension and associated complications. Hypertens Res 1996; 19 (Suppl 1):S87-S91.
54. Grodstein F, Stampfer JJ, Colditz GA, Willett WC, Manson JE, Joffe M, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336:1769-1775.
55. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS). JAMA 1998; 280:605-613.
56. Davey-Smith G, Neaton JD, Wentworth D, Stamler R, Stamler J. Socioeconomic differentials in mortality risk among men screened for the Multiple Risk Factor Intervention Trial: I. White men. Am J Public Health 1996;86:486-496.
57. Whitlock G, MacMahon S, Vander Hoorn S, Davis P, Jackson R, et al. Socioeconomic distribution of smoking in a population of 10, 529 New Zealanders. NZ Med J 1997; 110:327-330.
58. Sheth T, Bosch J, Chen J, Anand S, Nargundkar M, Nair C, et al. Ethnic differences in socioeconomic status and mortality [abstract]. Can J Cardiol 1997; 13 (Suppl C):89C.
59. Tipene-Leach D, Stewart A, Beaglehole R. Coronary heart disease mortality in Auckland Maori and Europeans. NZ Med J 1991; 104:55-57.
60. Lee EJ, Cowan LD, Welty TK, Sievers M, Howard WJ, Oopik A, et al. All-cause mortality and cardiovascular disease mortality in three American Indian populations, aged 45-74 years, 1984-1988: the Strong Heart Study. Am J Epidemiol 1998; 147:995-1008.
61. Broderick J, Brott T, Kothari R, Miller R, Khoury J, Pancioli A, et al. The Greater Cincinnati/Northern Kentucky Stroke Study: preliminary first-ever and total incidence rates of stroke among blacks. Stroke 1998; 29:415-421.
62. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Stamler J. End-stage renal disease in African-American and white men. JAMA 1997; 277:1293-1298.
63. Cappuccio FP. Ethnicity and cardiovascular risk: variations in people of African ancestry and South Asian origin. J Hum Hypertens 1997; 11:571-576.
64. Sheth T, Nair C, Nargundkar M, Anand S, Yusuf S. Cardiovascular and cancer mortality among Whites, South Asians, and Chinese in Canada from 1 979 to 1993: an analysis of 2.6 million deaths. Can Med Assoc J (in press).
65. WHO-MONICA Project, Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project: registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994; 90:583-612.
66. WHO-MONICA Project, Stegmayr B, Asplund K, Kuulasmaa K, Rajakangas A-M, Thorvaldsen P, Tuomilehto J. Stroke incidence and mortality correlated to stroke risk factors in the WHO MONICA Project: an ecological study of 18 populations. Stroke 1997; 28:1367-1374.
67. Yao C, Wu Z, Wu Y. The changing pattern of cardiovascular diseases in China. World Health Stat Q 1993; 46:113-118.
68. Collins R, Peto R, MacMahon S, Herbert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335:827-839.
69. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994; 50:272-298.
70. MacMahon S, Rodgers A. The effects of antihypertensive treatment on vascular disease: reappraisal of the evidence in 1994. J Vase Med Biol 1993;4:265-271.
71. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998; 279:1903-1907.
72. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ 1985; 291:97-104.
73. Medical Research Council Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304:405-412.
74. The IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomised trial of treatment based on the beta-blocker oxprenolol: the international prospective primary prevention study in hypertension (IPPPSH). J Hypertens 1985; 3:379-392.
75. Wilhelmsen L, Berglund G, Elmfeld D, Fitzsimons T, Holzgreve H, Hosie J, et al., on behalf of the Heart Attack Primary Prevention in Hypertension Trial Research Group. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 1987; 5:561-572.
76. Kostis JB, Davis BR, Cutler J, Grimm RH, Berge KG, Cohen JD, et al., for the SHEP Cooperative Research Group. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1997; 278:212-216.
77. Yusuf S, Thomas T, Abbott RD. Changes in hypertension treatment and in congestive heart failure mortality in the United States. Hypertension 1989; 13 (Suppl 0:174-179.
78. Staessen JA, Fagard R, Thijs L, Cells H, Arabidze GG, Birkenhager WH, et al., for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350:757-764.
79. Gong L, Zhang W, Zhu Y, Zhu J, Kong D, Page V, et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996; 14:1237-1245.
80. Liu L, Wang JG, Gong L, Liu G, Staessen JA, for the Systolic Hypertension in China (Syst-China) Collaborative Group. Comparison of active treatment and placebo for older Chinese patients with isolated systolic hypertension. J Hypertens 1998; 16:1823-1829.
81. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al., for the CAPPP Study Group. Principal results of the Captopril Prevention Project (CAPPP). Lancet (in press).
82. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265:3255-3264.
83. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317:713-720.
84. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Menard J, et al., for the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351:1755-1762.
85. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317:703-713.
86. Ad Hoc Subcommittee of the Liaison Committee of the World Health Organization and the International Society of Hypertension. Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. J Hypertens 1997; 15:105-115.
87. Lever AF, Hole DJ, Gillis CR, McCallum IR, Mclnnes GT, MacKinnon PL, et al. Do inhibitors of angiotensin-l-converting enzyme protect against risk of cancer? Lancet 1998; 352:179-184.
88. Forette F, Seux MC, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, et al., on behalf of the Syst-Eur investigators. Prevention of dementia in randomized double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352:1347-1351.
89. Mancia G, Sega R, Milesi C, Cesana G, Zanchetti A. Blood pressure control in the hypertensive population. Lancet 1997; 349:454-457.
90. Tao S, Wu X, Duan X, Fang W, Hao J, Fan D, et al. Hypertension prevalence and status of awareness, treatment and control in China. Chin Med J 1995; 108:483-489.
91. Isles CG, Walker LM, Beevers GD, Brown I, Cameron HL, Clarke J, et al. Mortality in patients of the Glasgow Blood Pressure Clinic. J Hypertens 1986;4:141-156.
92. Gamble G, MacMahon S, Culpan A, Ciobo C, Whalley G, Sharpe N. Atherosclerosis and left ventricular hypertrophy: persisting problems in treated hypertensive patients. J Hypertens 1998; 16:1389-1395.
93. Tang JL, Armitage JM, Lancaster T, Silagy CA, Fowler GH, Neil HAW. Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects. BMJ 1998; 316:1213-1220.
94. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
95. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al., for the West of Scotland Coronary Prevention Study group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333:1301-1307.
96. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al., for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335:1001-1009.
97. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al., for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Athero-sclerosis Prevention Study. JAMA 1998; 279:1615-1622.
98. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853.
99. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352:854-865.
100. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308:81-106.
101. Hennekens CH, Buring JE, Peto R. Antioxidant vitamins: benefits not yet proved. N Engl J Med 1 994; 330:1080-1081.
102. Mancia G, Parati G, Di Rienzo M, Zanchetti A. Blood pressure variability. In: Zanchetti A, Mancia G (editors): Handbook of hypertension: pathophysiology of hypertension. Amsterdam: Elsevier Science; 1997. 17:117-169.
103. Laragh JH, Brenner BM (editors). Hypertension: pathophysiology diagnosis and management. 2nd ed. New York: Raven Press; 1995. 2:1897-1952.
104. Swales JD (editor). Textbook of hypertension. London: Blackwell; 1994. ch55, pp. 989-1008.
105. Ohkubo T, Imai Y, Tsuji I, Nagai K, Kato J, Kikuchi N, et al. Home blood pressure measurement has a stronger predictive power for mortality than dose screening blood pressure measurement: a population-based observation in Ohasama, Japan. J Hypertens 1998; 16:971-975.
106. Mancia G, Di Rienzo M, Parati G. Ambulatory blood pressure monitoring use in hypertension research and clinical practice. Hypertension 1993; 21:510-524.
107. Mancia G, Sega R, Bravi D, De Vito G, Valagussa F, Cesana G, et al. Ambulatory blood pressure normality: results from the PAMELA Study. J Hypertens 1995; 13:1377-1390.
108. Pyorala K, Graham I, Mancia G, Poole-Wilson P, Wood D, on behalf of the Task Force. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J (in press).
109. Zanchetti A, Bond MG, Henning M, Neiss A, Mancia G, Dal Palu C, et al., on behalf of the ELSA Investigators. Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis. J Hypertens 1998; 16:949-961.
110. Fagard RH, Staessen JA, Thijs L. Prediction of cardiac structure and function by repeated clinic and ambulatory blood pressure. Hypertension 1997;29:22-29.
111. Perloff D, Sokolow M, Cowan R, Juster R. Prognostic value of ambulatory blood pressure measurement. J Hypertens 1989; 7 (Suppl 3):S3-S10.
112. Verdecchia P, Porcellati C, Shillaci G, Borgioni C, Ciucci A, Battistelli M. Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension 1994; 24:793-801.
113. Redon J, Campos C, Narciso ML, Rodicio JL, Pasquale JM, Ruilope LM. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension 1998; 31:712-718.
114. Ohkubo T, Imai Y, Tsuji I, Nagai K, Ito S, Satoh H, et al. Reference values for 24-hour ambulatory blood pressure monitoring based on a prognostic criterion: Ohasama study. Hypertension 1998; 32:255-259.
115. Mancia G, Zanchetti A, Agabiti-Rosei E, Benemio G, De Cesaris R, Fogari R, et al, for the SAMPLE Study Group. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regres-sion of left ventricular hypertrophy. Circulation 1997; 95:1464-1470.
116. Mancia G, Omboni S, Parati G. Assessment of antihypertensive treatment by ambulatory blood pressure. J Hypertens 1997; 15 (Suppl 2):S43-S50.
117. Pickering TG, James GD, Boddie C, Harshfield GA, Blank S. How common is white coat hypertension? JAMA 1988; 259:225-228.
118. Mancia G, Zanchetti A. White-coat hypertension: misnomers, misconceptions and misunderstandings. What should we do next? [Editor's Corner] J Hypertens 1996; 14:1049-1052.
119. Parati G, Ulian L, Santucciu C, Omboni S, Mancia G. Difference between clinic and daytime blood pressure is not a measure of the white coat effect. Hypertension 1998; 31:1185-1189.
120. Mancia G, Parati G, Pomidossi G, Grassi G, Casadei R, Zanchetti A. Alerting reaction and rise in blood pressure during measurement by physician and nurse. Hypertension 1987; 9:209-215.
121. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993; 153:154-183.
122. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997; 157:2413-2446.
123. The Guidelines Subcommittee of the WHO-ISH Mild Hypertension Liaison Committee. 1993 Guidelines for the Management of Mild Hypertension. Memorandum from a World Health Organization-International Society of Hypertension Meeting. J Hypertens 1993; 11:905-918.
124. Chalmers J, Zanchetti A. Reply to a critique of the 1996 World Health Organization expert committee report on hypertension. J Hypertens 1997; 15:684-685.
125. Lindholm L, Ejlertsson G, Schersten B. High risk of cerebrovascular morbidity in well treated male hypertensives: a retrospective study of 40-59 year old hypertensives in a Swedish primary care district. Acta Med Scand 1984; 216:251-259.
126. Silagy C, Mant D, Fowler G, Lodge M. Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet 1994; 343:139-142.
127. Stamler J. Epidemiologic findings on body mass and blood pressure in adults. Ann Epidemiol 1991; 1:347-362.
128. Reid CM, Dart AM, Dwar EM, Jennings GL. Interactions between the effects of exercise and weight loss on risk factors, cardiovascular haemodynamics and left ventricular structure in overweight subjects. J Hypertens 1994; 12:291-301.
129. Puddey IB, Parker M, Belling U, Vandongen R, Masarei JRL Effects of alcohol and caloric restrictions on blood pressure and serum lipids in overweight men. Hypertension 1992; 20:533-541.
130. Whelton PK, Appel U, Espeland MA, Applegate WB, Ettinger WH, Kostis JB, et al, for TONE Collaborative Research Group,. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the Elderly (TONE). JAMA 1998; 279:839-846.
131. Puddey IB, Beilin LJ, Rakic V. Alcohol, hypertension and the cardiovascular system: a critical appraisal. Addiction Biol 1997; 2:159-170.
132. Puddey IB, Beilin LJ, Vandongen R. Regular alcohol use raises blood pressure in treated hypertensive subjects: a randomized controlled trial. Lancet 1987; 1:647-651.
133. Law MR. Epidemiological evidence on salt and blood pressure. Am J Hypertens 1997; 10 (Suppl):42S-45S.
134. Cutler JA, Follman D, Alexander PS. Randomised controlled trials of sodium reduction: an overview. Am J Clin Nutr 1997; 65 (2 Suppl S): 643S-651S.
135. Rouse IL, Armstrong BK, Beilin LJ. The relationship of blood pressure to diet and lifestyle in two religious populations. J Hypertens 1983; 1:65-71.
136. Margetts BM, Beilin U, Vandongen R, Armstrong BK. Vegetarian diet in mild hypertension: a randomized controlled trial. BMJ 1986; 293:1468-1471.
137. Appel U, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 1997; 336:1117-1124.
138. Bao DG, Mori TA, Burke V, Puddey IB, Beilin U. Effects of dietary fish and weight reduction on ambulatory blood pressure in overweight hypertensives. Hypertension 1998; 32:710-717.
139. Jennings GLR. Exercise and blood pressure: walk, run or swim? J Hypertens 1997; 15:567-569.
140. Arakawa K. Antihypertensive mechanism of exercise. J Hypertens 1993; 11:223-229.
141. Fagard RH. The role of exercise in blood pressure control: supportive evidence. J Hypertens 1995; 13:1223-1227.
142. Puddey IB, Cox K. Exercise lowers blood pressure-sometimes? Or did Pheidippides have hypertension? J Hypertens 1995; 13:1229-1233.
143. Beilin U. Stress coping, lifestyle and hypertension: a paradigm for research prevention and non-pharmacological management of hypertension. Clin Exp Hypertens 1997; 19:739-752.
144. Lindquist TL, Beilin U, Knuiman MW. Influence of lifestyle, coping and job stress on blood pressure in men and women. Hypertension 1997; 29:1-7.
145. Nyklicek I, Vingerhoets JJM, Van Heck GL. Hypertension and objective and self-reported stressor exposure: a review. J Psychosom Res 1996; 40:585-601.
146. Pickering TG, Devereux RB, James GD, Gerin W, Landsbergis P, Schnall PL, et al. Environmental influences on blood pressure and the role of job strain. J Hypertens 1996; 14 (Suppl 5):S179-S185.
147. Parati G, Pomidossi G, Albini F, Malaspina D, Mancia G. Relationship of 24 hour blood pressure mean and variability to severity of target organ damage in hypertension. Hypertension 1987; 5:93-98.
148. Frattola A, Parati G, Cuspidi G, Albini F, Mancia G. Prognostic value of 24 hour blood pressure variability. J Hypertens 1993; 11:1133-1137.
149. Siscovick D, Raghunathan T, Psaty B, Keopsell T, Wicklund K, Xiphong Lin M, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994; 330:1852-1857.
150. Hoes A, Grobbee D, Lubsen J, Man in't Veld A, Van der Does E, Hofman A. Diuretics, beta-blockers, and the risk of sudden cardiac death in hypertensive patients. Ann Intern Med 1995; 123:481-187.
151. Doughty R, Rodgers A, Sharpe N, MacMahon S. Effects of beta-blocker therapy on mortality in patients with heart failure. Eur Heart J 1997; 18:560-565.
152. Yasue H, Kugiyama K. Coronary spasm: Japanese view. Coronary Artery Dis 1990; 1:668-673.
153. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273:1450-1456.
154. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy: the Collaborative Study Group. N Engl J Med 1993; 329:1456-1462.
155. Israili Z, Hall W. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: a review of the literature and pathophysiology. Ann Intern Med 1992; 117:234-242.
156. Johnston C. Angiotensin receptor antagonists: focus on losartan. Lancet 1995;346:1403-1407.
157. Neaton JD, Grimm RH, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, et al., for the Treatment of Mild Hypertension Study Research Group. Treatment of Mild Hypertension Study: final results. JAMA 1993; 270:713-724.
158. Brown MA, Whitworth JA. Pregnancy. In: Bennett WM, McCarron DA (editors): Contemporary issues in nephrology: pharmacology and management of hypertension. Vol. 28. New York: Churchill Livingstone; 1994. pp. 89-116.
159. Cooper RS, Liao Y, Rotimi C. Is hypertension more severe among US blacks, or is severe hypertension more common? Ann Epidemiol 1996; 6:173-180.
160. Bullen C, Tipene-Leach D, Vander Hoorn S, Jackson R, Norton R, MacMahon S. Ethnic differences in blood pressure: findings from the Fletcher Challenge-University of Auckland University Heart and Health Study. NZ Med J 1996; 109:395-397.
161. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration. Protocol for prospective collaborative overviews of major randomized trials of blood pressure lowering treatments. J Hypertens 1998; 16:127-137.
162. National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program Working Group Report on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 1990; 163:1689-1712.
163. Australasian Society for the Study of Hypertension in Pregnancy. Management of hypertension in pregnancy: executive summary. Med J Aust 1993; 158:700-702.
164. Collins R, Yusuf S, Peto R. Overview of randomised trials of diuretics in pregnancy. BMJ Clin Res Ed 1985; 290:17-23.
165. CLASP Collaborative Group. CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. Lancet 1994; 343:619-629.
166. MacMahon S, Rodgers A. The effects of blood pressure reduction in older patients: an overview of five randomized controlled trials in elderly hypertensives. J Clin Exp Hypertens 1993; 15:967-978.
167. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-Hypertension). Lancet 1991; 338:1 281-1285.
168. Staessen JA, Fagard R, Thijs L, Cells H, Birkenhager WH, de Leeuw PW, et al., for the Systolic Hypertension in Europe Trial Investigators. Subgroup and per-protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Arch Intern Med 1998; 158:1681-1691.
169. The INDANA (INdividual Data ANalysis of Antihypertensive interventional trials) Project Collaborators, Gueyffier F, Boissel J-P, Boutitie F, Pocock S, Coope J, Cutler J, et al. Effect of antihypertensive treatment in patients having already suffered from stroke: gathering the evidence. Stroke 1997; 28:2557-2562.
170. PROGRESS Management Committee. Blood pressure lowering for the secondary prevention of stroke: rationale and design for PROGRESS. J Hypertens 1996; 14 (Suppl 2):S41-S46.
171. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27:335-371.
172. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994; 90:2056-2069.
173. The HOPE Study Investigators. The HOPE (Heart Outcome Prevention Evaluation) Study: the design of a large, simple randomised trial of an angiotensin converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Can J Cardiol 1996; 12:127-137.
174. Brown MA, Whitworth JA. Hypertension in human renal disease. J Hypertens 1992; 10:701-712.
175. Iseki K, Ikemiya Y, Fukiyama K. Blood pressure and risk of end-stage renal disease in a screened cohort. Kidney Int 1996; 49 (Suppl 55):S69-S71.
176. Rite E, Rambausek M, Hasslacher C, Mann J. Pathogenesis of hyper-tension in renal disease. Am J Nephrol 1989; 9:85-90.
177. Krolewski AS, Canessa M, Warran JH, Laffel LMB, Christlich AR, Knowler WC, et al. Predisposition to hypertension and susceptibility to renal disease in insulin dependent diabetes mellitus. N Engl J Med 1988; 318:140-145.
178. Bergstrom J, Alvestrand A, Bucht H, Gutierrez A. Progression of chronic renal failure in man is retarded with more frequent clinical follow-ups and better blood pressure control. Clin Nephrol 1986; 25:1-6.
179. Ihle BU, Whitworth JA, Shahinfar S, Cnaan A, Kincaid-Smith PS, Becker GJ. Angiotensin converting enzyme inhibition in non-diabetic progressive renal insufficiency: a controlled double-blind trial. Am J Kidney Dis 1996; 27:489-495.
180. Peterson JC, Adler S, Bukart JM, Greene T, Hebert LA, Hunsicker LG, et al., for the Modification of Diet in Renal Disease (MDRD) Study Group. Blood pressure control, proteinuria and the progression of renal disease. Ann Intern Med 1995; 123:754-762.
181. Simonson DC. Etiology and prevalence of hypertension in diabetic patients. Diabetes Care 1988; 11:821-827.
182. Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension 1992;19:403-418.
183. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1 996; 334:374-381.
184. Haffner SM. Insulin and blood pressure: fact or fantasy? J Clin Endocrinol Metab 1993; 76:541-542.
185. Grossman E, Messerli FH. Diabetic and hypertensive heart disease. Ann Intern Med 1996; 125:304-310.
186. Borch-Johnson K, Nissen R, Nerup J. Blood pressure after 40 years of insulin-dependent diabetes. Nephron 1985; 4:11-12.
187. Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ 1982; 285:685-688.
188. Knowler WC, Bennett PH, Ballintine EJ. Increased incidence of retinopathy in diabetics with elevated blood pressure. N Engl J Med 1980; 302:645-650.
189. Chaturvedi N, Sjolie A-K, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, et al., and the EUCLID Study Group. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998; 351:28-31.
190. Su HY, Sheu WH, Chin HM, Jeng CY, Chen YD, Reaven GM. Effect of weight loss on blood pressure and insulin resistance in normotensive and hypertensive obese individuals. Am J Hypertens 1995; 8:1067-1071.
191. Su HY, Sheu WH, Chin HM, Jeng CY, Chen YD, Reaven GM. Effect of weight loss on blood pressure and insulin resistance in normotensive and hypertensive obese individuals. Am J Hypertens 1995; 8:1067-1071.
192. Lithell HO. Hyperinsulinemia, insulin resistance, and the treatment of hypertension. Am J Hypertens 1996; 9 (Suppl):150S-154S.
193. Kjekshus J, Gilpin E, Call G, Blackey AR, Henning H, Ross J. Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J 1990;11:43-50.
194. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21:597-603.
195. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared to enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. NEngl J Med 1998; 338:645-652.
196. Ruilope LM, Garcia-Robles R. How far should blood pressure be reduced in diabetic hypertensive patients? J Hypertens 1997; 15 (Suppl 2):S63-S65.
197. Lomas J. Words without action? The production, dissemination and impact of consensus recommendations. Annu Rev Public Health 1991; 12:41-65.
198. Davis DA, Thomson MA, Oxman AD, Haynes RB. Evidence for the effectiveness of CME: a review of 50 randomised controlled trials. JAMA 1992;268:1111-1117.
199. Oxman AD, Thomson MA, Davis DA, Haynes RB. No magic bullets: a systematic review of 102 trials of interventions to improve professional practice. Can Med Assoc J 1995; 153:1423-1431.
200. Grol R, Dalhuijsen J, Thomas S, in 't Veld C, Rutten G, Mokkink H. Attributes of clinical guidelines that influence use of guidelines in general practice: observational study. BMJ 1998; 317:858-861.